In fact, pancreatic adenocarcinoma is characterized by several germline or acquired genetic mutations, the most common being KRAS (90%), CDK2NA (90%), TP53 (75–90%), SMAD4/DPC4 (50%). This evidence concerns the gene SMAD4 and pancreatic adenocarcinoma.